IGC Pharma, Inc. (IGC) earnings date, results and what the price requires
NYSE · SEC CIK 0001326205 · SEC filings checked Oct 17, 2026
Next report
Nov 13, 2026
Estimated from reporting history (92-day cycle, SEC periodic report filing dates). Not confirmed.
Last close
$0.25
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
—
Needs four consecutive reported quarters.
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | $265,000 | $-2.9M | $-0.03 | Filing |
| Mar 31, 2026 | May 15, 2026 | $317,000 | $-2.4M | $-0.02 | Filing |
| Sep 30, 2025 | Nov 14, 2025 | $191,000 | $-1.8M | $-0.02 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | $328,000 | $-1.6M | $-0.02 | Filing |
| Mar 31, 2025 | Jun 27, 2025 | $330,000 | $-1.2M | $-0.02 | Filing |
| Dec 31, 2024 | Feb 14, 2025 | $257,000 | $-1.8M | $-0.02 | Filing |
| Sep 30, 2024 | Nov 12, 2024 | $412,000 | $-1.7M | $-0.02 | Filing |
| Jun 30, 2024 | Aug 7, 2024 | $272,000 | $-2.4M | $-0.03 | Filing |
What would IGC Pharma, Inc. have to report for its valuation to change?
Four consecutive reported quarters of diluted EPS are not available in SEC filings. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.